Does Serum CAR-3 Play a Role in Pancreatic Cancer Diagnosis?

Basso, Daniela; Panozzo, M.P.; Fabris, Carlo; Meggiato, T.; Faggian, Diego; Fogar, Paola; Scalon, P; Favero, G. Del; Plebani, Mario; Burlina, Angelo; Naccarato, R.

doi:10.1159/000226888

Cited by 4 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As gallbladder bile cannot be drained into the bile ducts in GBC and in other biliary diseases causing biliary obstruction, the increased pressure in the biliary system leads to bile duct dilation, inflammatory response, and elevation of TB levels 25 , resulting in an elevation of serum CA19-9 levels 26 , 27 . Furthermore, as the liver is the main metabolic and clearance organ of CA19-9, its function is impaired in biliary obstruction, leading to a reduction in metabolism and clearance of CA19-9, resulting in an increase in the serum level of CA19-9 in these patients 28 . Thus, this study was designed to predict the prognosis of GBC patients after curative-intent resection using an adjusted CA19-9 to decrease the impact of elevated serum TB levels on CA19-9 to reflect the more authentic and accurate serum CA19-9 levels.…”

Section: Discussionmentioning

confidence: 99%

Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Li,

Liu,

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

Background: The prognostic value of carbohydrate antigen 19-9 (CA19-9) is known to be affected by elevated bilirubin levels in patients with gallbladder carcinoma (GBC). The clinical significance of changes in the ratio of CA19-9 levels to total bilirubin (TB) levels in patients with GBC after curative-intent resection remains unknown. The aim of this study was to determine the prognostic value of changes in preoperative and postoperative CA19-9/TB ratio in these patients. Methods: Prospectively colleced data on consecutive patients who underwent curative-intent resection for GBC between January 2015 and December 2020 stored in a multicenter database from 10 hospitals were analysed in this retrospective cohort study. Based on the adjusted CA19-9 defined as the ratio of CA19-9 to TB, and using 2×103 U/µmol as the upper normal value, patients were divided into a normal group (with normal preoperative and postoperative adjusted CA19-9), a normalization group (with abnormal preoperative but normal postoperative adjusted CA19-9), and a non-normalization group (with abnormal postoperative adjusted CA19-9). The primary outcomes were overall survival (OS) and recurrence-free survival (RFS). The log-rank test was used to compare OS and RFS among the groups. The Cox regression model was used to determine factors independently associated with OS and RFS. Results: The normal group (n=179 patients) and the normalization group (n=73 patients) had better OS and RFS than the non-normalization group (n=65 patients) (the 3-year OS rates 72.0%, 58.4% and 24.2%, respectively; the RFS rates 54.5%, 25.5% and 11.8%, respectively; both P<0.001). There were no significant differences between the normal and the normalization groups in OS and RFS (OS, P=0.255; RFS, P=0.130). Cox regression analysis confirmed that the non-normalization group was independently associated with worse OS and RFS. Subgroup analysis revealed that the non-normalization group of patients who received adjuvant therapy had significantly improved OS and RFS as compared to those who did not receive adjuvant therapy (OS, P=0.025; RFS, P=0.003). Conclusions: Patients with GBC who underwent curative-intent surgical resection with postoperative abnormal levels of adjusted CA19-9 (the CA19-9/TB ratio) were associated with poorer long-term survival outcomes. Adjuvant therapy after surgery improved the long-term outcomes of these patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Li,

Liu,

et al. 2024

International Journal of Surgery

View full text Add to dashboard Cite

show abstract

“…Using this technique, various epitopes are now detectable in biological fluids (CA 19-9, CA 50, CAR-3, DU-PAN-2 and others) [ 1,4,6,9,19]. They are all borne on glycopro tein macromolecules and in some cases the same macro molecule bears two or more epitopes [11][12][13][14], To date, the best serological indicator of pancreatic adenocarcinoma is CA 19-9, an epitope of a mucin-type glycoprotein identical to the sialylated Lewis a antigen, and recognized by the antibody 1116 NS 19-9 [8,11,15,16], However, CA 19-9 determination has demonstrated some limitation in pancreatic cancer diagnosis: (1) it is not sensitive enough to suggest the presence of a tumour at an early stage [17,18], and (2) its circulating levels are influenced by any liver dysfunction, and jaundice in par ticular [5,[19][20][21],…”

Section: Introductionmentioning

confidence: 99%

Is CA 242 Really a New Tumour Marker for Pancreatic Adenocarcinoma?

Plebani

Basso²,

Navaglia³

et al. 1995

Oncology

View full text Add to dashboard Cite

CA 242, a sialylated carbohydrate epitope situated on the same macromole-cule as CA 50 has been proposed as a new tumour marker for pancreatic cancer (PC). The aims of the present study were: (1) to evaluate serum CA 242 versus CA 19-9 in PC patients, and (2) to assess whether these markers can predict tumour spread or patient survival. We studied 59 healthy controls, 27 PC patients, 12 chronic pancreatitis cases, 107 with extra-pancreatic gastrointestinal tumours, 30 with benign jaundice and 24 with benign extra-pancreatic gastrointestinal diseases. Mean CA 242 values were significantly higher in PC than in any other group; CA 19-9 showed a similar pattern. The best diagnostic efficacy (ROC curves analysis) in diagnosing PC was 86% for CA 242 and 84% for CA 19-9, using cut-off values of 60 and 80 U/ml, respectively. In PC, serum levels of both markers were unrelated to tumour spread or size; in PC patients with high levels of CA 242 or CA 19-9 survival was significantly shorter. CA 242 and CA 19-9 were correlated both when considering all the patients together (r = 0.962, p < 0.001) and PC alone (r = 0.880, p < 0.001). Given the very close relationship between CA 242 and CA 19-9, we tested for cross-reactivity between CA 242 antigen and CA 19-9 antibody: CA 242 antigen with CA 19-9 antibody produced a similar curve to CA 242 antigen and its corresponding antibody. In conclusion, CA 242 showed similar diagnostic value to CA 19-9 in assessing PC patients; both seem unrelated to tumour size or spread, but seem to predict survival. Their remarkably similar behaviour is due to cross-reactivity between CA 242 antigen and CA 19-9 antibody, so CA 242 cannot, in our opinion, be considered a new tumour marker for PC.

show abstract

SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker

Frena

2001

Int J Biol Markers

View full text Add to dashboard Cite

show abstract

Does Serum CAR-3 Play a Role in Pancreatic Cancer Diagnosis?

Cited by 4 publications

References 5 publications

Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Long-term prognosis of patients with gallbladder carcinoma after curative-intent resection based on changes in the ratio of carbohydrate antigen 19-9 to total bilirubin (CA19-9/TB): a multicenter retrospective cohort study

Is CA 242 Really a New Tumour Marker for Pancreatic Adenocarcinoma?

SPan-1 and Exocrine Pancreatic Carcinoma. The Clinical Role of a New Tumor Marker

Contact Info

Product

Resources

About